A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker ( HLA-B 5701) in subjects with and without hypersensitivity to abacavir.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2007
At a glance
- Drugs Abacavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacogenomic
- Sponsors GlaxoSmithKline
- 01 Aug 2007 Status changed from in progress to completed.
- 05 May 2007 Interim results have been reported.
- 16 Feb 2007 Status changed from recruiting to in progess.